Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elicio Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company focused on cancer immunotherapies. Its disclosures cover common stock registered on The Nasdaq Capital Market, emerging growth company reporting status, operating and financial results, corporate updates, and material-event reports.
Recent filings also address capital-structure matters, including an at-the-market equity program tied to a Form S-3 registration statement, as well as Regulation FD and other event disclosures for ELI-002, AMPLIFY-7P, AMPLIFY-201, mKRAS-specific T cell response data, scientific publications, governance matters, shareholder voting topics, and risk-related clinical and regulatory updates.
Elicio Therapeutics reported a net loss of $11.8 million for the three months ended March 31 2026, as it continues developing its AMP-based cancer immunotherapies. Operating expenses were $10.6 million, led by $6.8 million in research and development and $3.8 million in general and administrative costs.
Cash and cash equivalents were $14.9 million with total assets of $22.7 million and stockholders’ deficit of $1.4 million as of March 31 2026. Management discloses substantial doubt about the company’s ability to continue as a going concern, estimating its current cash runway extends into the fourth quarter of 2026.
To bolster liquidity, Elicio raised net proceeds of about $8.0 million in the quarter through at-the-market equity programs and carries a $10.0 million Senior Secured Promissory Note bearing interest of up to 12.5%. The company expects continued losses as it advances its Phase 2 ELI-002 7P program and preclinical pipeline.
Elicio Therapeutics reported first quarter 2026 results and highlighted progress in its Phase 2 AMPLIFY-7P trial of ELI-002 7P in KRAS-driven pancreatic cancer. The primary disease-free survival analysis is expected mid-year 2026, and fewer disease progressions and deaths than projected have been observed so far.
R&D expenses were $6.8 million versus $7.8 million a year earlier, while G&A expenses rose to $3.8 million from $3.0 million. Net loss was $11.8 million compared to $11.2 million, with net loss per share improving to $0.65 from $0.87.
Cash and cash equivalents were $14.9 million at March 31, 2026, down from $18.6 million at December 31, 2025. The company raised approximately $13.0 million through its at-the-market program in Q1 and early Q2 2026 and now expects its cash runway to extend into Q4 2026, beyond the anticipated AMPLIFY-7P DFS readout.
Elicio Therapeutics, Inc. files Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive compensation, corporate governance and security ownership that was omitted from the original 10-K.
The filing reports an aggregate market value of common stock held by non-affiliates of approximately $81.8 million based on the Nasdaq Capital Market closing price on June 30, 2025. Shares of common stock outstanding were 18,704,798 as of April 9, 2026.
Elicio Therapeutics, Inc. entered into an at-the-market stock sales program allowing it to issue and sell up to $100.0 million of common stock from time to time through B. Riley Securities, JonesTrading and Ladenburg Thalmann under a new Sales Agreement.
Sales will be made pursuant to an effective Form S-3 shelf registration, with the agents earning a 3.0% commission on gross proceeds. The company is not required to sell any shares and can terminate the arrangement on short notice.
Elicio also terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had allowed sales of up to $40.0 million of common stock, and confirmed there are no termination penalties and no further shares may be sold under that earlier program.
Elicio Therapeutics is offering up to $100,000,000 of common stock in an “at the market” (ATM) sales program. The company may sell shares from time to time through B. Riley Securities, JonesTrading or Ladenburg Thalmann under a March 16, 2026 Sales Agreement.
The Sales Agents will be paid a 3.0% commission and may act as agents or principals. Net proceeds are intended to fund research and clinical development (including ELI-002 programs), with remaining amounts for working capital and general corporate purposes. The prospectus supplement cites 17,800,307 shares outstanding as of December 31, 2025 and illustrates an example assuming $100,000,000 of sales at $12.20 per share.
Elicio Therapeutics is registering up to $400,000,000 of securities on a shelf to be sold from time to time, consisting of common stock, preferred stock, debt securities, warrants and units.
The pre-effective amendment updates the prospectus to incorporate the Company’s Annual Report on Form 10-K filed March 12, 2026, revises the Risk Factors and Experts sections, refreshes the corporate overview and forward-looking statements, and files the independent auditors’ consent as Exhibit 23.1. The prospectus states net proceeds will be used for working capital, research and development, business expansion, strategic transactions and general corporate purposes, with specific terms to be provided in prospectus supplements. The filing also notes recent clinical program context: the Phase 2 AMPLIFY-7P study of ELI-002 7P continued to final analysis after an IDMC interim review and the company anticipates a final disease-free survival analysis in the first half of 2026. The Company’s common stock traded at $12.90 on Nasdaq on March 10, 2026.
Elicio Therapeutics, Inc. files its annual report describing a clinical-stage oncology pipeline built on its lymph node–targeting Amphiphile (AMP) immunotherapy platform. The lead candidate, ELI-002 7P, targets seven common KRAS mutations in pancreatic and other solid tumors and is in a randomized Phase 2 PDAC trial.
Phase 1 data for ELI-002 2P and 7P showed high KRAS-specific T cell response rates, tumor biomarker declines, and encouraging relapse-free and overall survival signals. Elicio is also advancing preclinical AMP vaccines ELI-007 for BRAF-driven cancers and ELI-008 for TP53-mutant tumors, supported in part by research grants and an exclusive AMP license from MIT.
Elicio Therapeutics reported 2025 results and highlighted progress for its lead KRAS-targeted cancer immunotherapy ELI-002 7P. R&D expense fell to $24.9 million from $33.7 million in 2024 as its Phase 2 AMPLIFY-7P trial moved more patients into observation, while G&A rose to $12.8 million from $11.3 million. Net loss narrowed to $39.5 million, or $2.58 per share, from $51.9 million, or $4.25 per share. Cash and cash equivalents were $18.6 million as of December 31, 2025, up from $17.6 million a year earlier, helped by at-the-market equity proceeds of about $4.9 million in Q4 2025 and $6.3 million in Q1 2026 to date.
The company reiterated that its cash plus expected at-the-market proceeds are projected to fund operations into Q3 2026, beyond the anticipated event-driven primary disease-free survival analysis for the Phase 2 AMPLIFY-7P trial in the first half of 2026. Elicio reported fewer disease progressions and deaths than projected to date in this randomized study and plans to seek an End-of-Phase 2 meeting with the FDA, finalize a Phase 3 protocol, and advance ELI-002 7P toward a registrational trial in resected mKRAS pancreatic cancer, while exploring expansion into neoadjuvant, metastatic PDAC and other mKRAS-positive tumors.
Elicio Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (S-3/A) to delay the registration statement’s effective date by including the cover-page delaying amendment language.
The amendment states it does not modify the prospectus, includes an expenses table showing a SEC registration fee of $55,240.00 and a FINRA filing fee of $60,500.00, and describes indemnification provisions under Delaware law, the company’s charter and bylaws, director and officer indemnification agreements, a six-year indemnity/anti-amendment covenant tied to a Merger Agreement, and a six-year prepaid tail D&O policy.